The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China

Jiujie Cui; Qihan Fu; Xiaobing Chen; Yanling Wang; Qi Li; Feng Wang; Zhihua Li; Guanghai Dai; Yusheng Wang; Hongmei Zhang; Houjie Liang; Jun Zhou; Liu Yang; Fenghua Wang; Leizhen Zheng; Xiaofeng Chen; Ping Gong; Jiang Liu; Ying Yuan; Lin Wang; Yuejuan Cheng; Jun Zhang; Yuhong Zhou; Weijian Guo; Xianbao Zhan; Zhengyun Zou; Da Li; Shan Zeng; Enxiao Li; Zhiwei Li; Zan Teng; Dan Cao; Jie Kan; Jianping Xiong; Ming Quan; Jiayu Yao; Haiyan Yang; Liwei Wang

doi:10.1097/JP9.0000000000000155

Journal of Pancreatology (Mar 2024)

The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China

Jiujie Cui,
Qihan Fu,
Xiaobing Chen,
Yanling Wang,
Qi Li,
Feng Wang,
Zhihua Li,
Guanghai Dai,
Yusheng Wang,
Hongmei Zhang,
Houjie Liang,
Jun Zhou,
Liu Yang,
Fenghua Wang,
Leizhen Zheng,
Xiaofeng Chen,
Ping Gong,
Jiang Liu,
Ying Yuan,
Lin Wang,
Yuejuan Cheng,
Jun Zhang,
Yuhong Zhou,
Weijian Guo,
Xianbao Zhan,
Zhengyun Zou,
Da Li,
Shan Zeng,
Enxiao Li,
Zhiwei Li,
Zan Teng,
Dan Cao,
Jie Kan,
Jianping Xiong,
Ming Quan,
Jiayu Yao,
Haiyan Yang,
Liwei Wang

Affiliations

Jiujie Cui: a Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Qihan Fu: b Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Xiaobing Chen: c Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
Yanling Wang: a Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Qi Li: d Department of Medical Oncology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
Feng Wang: e Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Zhihua Li: f Department of Medical Oncology, Sun Yat-sen Medical Hospital Sun Yat-sen University, Guangzhou, China
Guanghai Dai: g Medical Oncology, Chinese PLA General Hospital, Beijing, China
Yusheng Wang: h Department of Gastrointestinal Oncology, Shanxi Provincial Cancer Hospital, Affiliated to Shanxi Medical University, Taiyuan, China
Hongmei Zhang: i Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, Xi’an, China
Houjie Liang: j Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Military Medical University), Chongqing, China
Jun Zhou: k Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China
Liu Yang: l Cancer Center, Department of Medical Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China
Fenghua Wang: m Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China
Leizhen Zheng: n Oncology Department, Xin Hua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China
Xiaofeng Chen: o Department of Oncology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, China
Ping Gong: p Department of Oncology, The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, China
Jiang Liu: q Department of Oncology, People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, China
Ying Yuan: r Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
Lin Wang: s Department of Medical Oncology, Hainan Genderal Hospital, Haikou, China
Yuejuan Cheng: t Division of Medical Oncology, Peking Union Medical College Hospital, Beijing, China
Jun Zhang: u Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Yuhong Zhou: v Department of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China
Weijian Guo: w Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Xianbao Zhan: x Department of Medical Oncology, Changhai Hospital of Shanghai, Navy Medical University, Shanghai, China
Zhengyun Zou: y Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, China
Da Li: z Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, China
Shan Zeng: aa Department of Medical Oncology, Xiangya Hospital Central South University, Changsha, China
Enxiao Li: bb Department of Medical Oncology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
Zhiwei Li: cc Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
Zan Teng: dd Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
Dan Cao: ee Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China
Jie Kan: ff Department of Medical Oncology, Qinghai Provincial People’s Hospital, Xi’ning, China
Jianping Xiong: gg Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
Ming Quan: hh Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
Jiayu Yao: a Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Haiyan Yang: a Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Liwei Wang: a Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

DOI: https://doi.org/10.1097/JP9.0000000000000155
Journal volume & issue: Vol. 7, no. 1
pp. 1 – 9

Abstract

Read online

Objective:. Real-world diagnostic and treatment data for pancreatic cancer in China are lacking. As such, the present study investigated the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer (including locally advanced and metastatic disease) in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center database. Methods:. A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a database. The entire course of real-world pancreatic cancer management was analyzed. Results:. The proportion of patients with advanced pancreatic cancer was higher among males than females (62.4% vs 37.6%, respectively). Patients typically had a history of hypertension (30.8%), diabetes (21.6%), and cholangitis (20.2%). Abdominal pain (51.6%), abdominal distension (27.1%), jaundice (20.1%), and weight loss (16.3%) were the main symptoms observed in patients with advanced pancreatic cancer in this cohort. Serum carbohydrate antigen (CA)19-9 is one of the most common tumor markers. In the present study, 2562 patients underwent first-line therapy. The median progression-free survival (PFS) for patients undergoing first-line therapy was 4.1 months. The major options for first-line therapy included gemcitabine (GEM) plus S-1 (GS/X) (23.4%), nab-paclitaxel plus GEM (AG) (18.1%), oxaliplatin, irinotecan, and leucovorin-modulated fluorouracil (FOLFIRINOX; 11.9%), nab-paclitaxel plus S-1 (AS) (8.9%), and GEM combined with oxaliplatin/cisplatin (GEMOX/GP) (7.6%). The AS and GS/X regimens were associated with the highest PFS rates. Conclusion:. This is the first study to report multicenter, real-world data regarding advanced pancreatic cancer in China. Results revealed that real-world treatment options differed from guideline recommendations, and PFS was shorter than that in previously reported data. Improving intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recommended.

Published in Journal of Pancreatology

ISSN: 2096-5664 (Print); 2577-3577 (Online)
Publisher: Wolters Kluwer Health/LWW
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
Website: https://journals.lww.com/jpancreatology/pages/default.aspx

About the journal